Clinical Trial

Scalp Cooling in MBC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-07-22; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2022-01-18
Trial Details
NCT Number NCT04986579
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences
Conditions Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Enrollment 120 participants
Start Date 2021-10-07
Primary Completion 2028-06-01 (estimated)
Study Completion 2030-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18